Timothy Rolph Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 12,500 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $44.53, for a total value of $556,625.00. Following the transaction, the insider now owns 170,237 shares in the company, valued at approximately $7,580,653.61. This represents a 6.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Wednesday, February 5th, Timothy Rolph sold 18,750 shares of Akero Therapeutics stock. The shares were sold at an average price of $56.51, for a total value of $1,059,562.50.
• On Monday, January 27th, Timothy Rolph sold 31,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $55.77, for a total transaction of $1,742,812.50.
• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.91, for a total transaction of $148,924.38.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock traded down $1.55 during trading on Friday, hitting $42.12. 947,726 shares of the company’s stock were exchanged, compared to its average volume of 857,391. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of -11.23 and a beta of -0.19. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The business has a 50-day simple moving average of $40.21 and a 200-day simple moving average of $33.07. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, research analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AKRO. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Morgan Stanley boosted their target price on Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. HC Wainwright boosted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Canaccord Genuity Group increased their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics presently has a consensus rating of “Buy” and an average price target of $76.29.

Institutional Trading of Akero Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP increased its holdings in Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after buying an additional 2,782,029 shares during the last quarter. Janus Henderson Group PLC grew its stake in Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock worth $203,053,000 after buying an additional 201,225 shares during the last quarter. RTW Investments LP increased its position in Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock worth $190,840,000 after buying an additional 940,388 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Akero Therapeutics by 13.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,321,972 shares of the company’s stock valued at $120,238,000 after acquiring an additional 513,613 shares during the period. Finally, Vanguard Group Inc. grew its position in Akero Therapeutics by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 3,704,411 shares of the company’s stock worth $103,057,000 after purchasing an additional 27,830 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.